KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Consolidated Net Income: 2018-2025

Historic Consolidated Net Income for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to $91.3 million.

  • BioNTech SE's Consolidated Net Income fell 30.31% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$516.0 million, marking a year-over-year decrease of 188.70%. This contributed to the annual value of -$710.9 million for FY2024, which is 171.03% down from last year.
  • BioNTech SE's Consolidated Net Income amounted to $91.3 million in Q3 2025, which was up 119.26% from -$474.1 million recorded in Q2 2025.
  • BioNTech SE's Consolidated Net Income's 5-year high stood at $8.4 billion during Q3 2021, with a 5-year trough of -$865.6 million in Q2 2024.
  • Moreover, its 3-year median value for Consolidated Net Income was $91.3 million (2025), whereas its average is -$7.7 million.
  • Per our database at Business Quant, BioNTech SE's Consolidated Net Income skyrocketed by 13,561,721,438.29% in 2021 and then slumped by 138.63% in 2024.
  • Quarterly analysis of 5 years shows BioNTech SE's Consolidated Net Income stood at $7.2 billion in 2021, then tumbled by 42.08% to $4.1 billion in 2022, then crashed by 77.48% to $934.5 million in 2023, then slumped by 60.79% to $366.4 million in 2024, then plummeted by 30.31% to $91.3 million in 2025.
  • Its Consolidated Net Income was $91.3 million in Q3 2025, compared to -$474.1 million in Q2 2025 and -$499.6 million in Q1 2025.